Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23170868 | 1.00 | BTK (1.00) | BTK | |
| SCHEMBL23170689 | 1.00 | BTK (1.00) | BTK | |
| SCHEMBL16828253 | 0.89 | BTK (1.00) | BTK | |
| SCHEMBL16828234 | 0.88 | BTK (1.00) | BTK | |
| SCHEMBL16828237 | 0.87 | BTK (1.00) | BTK | |
| SCHEMBL16828258 | 0.87 | BTK (1.00) | BTK | |
| SCHEMBL18167384 | 0.86 | BTK (1.00) | BTK | |
| SCHEMBL18167395 | 0.86 | BTK (1.00) | BTK | |
| SCHEMBL16828203 | 0.86 | BTK (1.00) | BTK | |
| SCHEMBL16828250 | 0.86 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637486-B2 | Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | claimed |
| US-20160311820-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | claimed |
| US-11739090-B2 | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors | JUMBO DRUG BANK CO., LTD. (CN) | 2023-08-29 | — | — | US | disclosed |
| US-11739090-B2 | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors | JUMBO DRUG BANK CO., LTD. (CN) | 2023-08-29 | — | — | US | disclosed |
| WO-2021057893-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS SELECTIVE BTK KINASE INHIBITORS | 南京明德新药研发有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3082809-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-20 | — | — | EP | disclosed |
| US-9637486-B2 | Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160311820-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311820-A1 | BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885 |
| US-11739090-B2 | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors | BTK, SYK, LCK | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.